Literature DB >> 8614422

Brief report: hepatic dysfunction as a complication of adenosine deaminase deficiency.

M E Bollinger1, F X Arredondo-Vega, I Santisteban, K Schwarz, M S Hershfield, H M Lederman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8614422     DOI： 10.1056/NEJM199605233342104

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  31 in total

1.  Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome.

Authors:  Olga Nikolajeva; Austen Worth; Rosie Hague; Nuria Martinez-Alier; Joanne Smart; Stuart Adams; E Graham Davies; H Bobby Gaspar
Journal:  J Clin Immunol       Date:  2015-04-15       Impact factor: 8.317

2.  Comparison of elapegademase and pegademase in ADA-deficient patients and mice.

Authors:  L Murguia-Favela; W Min; R Loves; M Leon-Ponte; E Grunebaum
Journal:  Clin Exp Immunol       Date:  2020-02-09       Impact factor: 4.330

3.  Somatic mosaicism caused by monoallelic reversion of a mutation in T cells of a patient with ADA-SCID and the effects of enzyme replacement therapy on the revertant phenotype.

Authors:  M Moncada-Vélez; A Vélez-Ortega; J Orrego; I Santisteban; J Jagadeesh; M Olivares; N Olaya; M Hershfield; F Candotti; J Franco
Journal:  Scand J Immunol       Date:  2011-11       Impact factor: 3.487

4.  Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency.

Authors:  Robert Sokolic; Irina Maric; Chimene Kesserwan; Elizabeth Garabedian; I Celine Hanson; Margaret Dodds; Rebecca Buckley; Andrew C Issekutz; Naynesh Kamani; Kit Shaw; Ben Tan; Pawan Bali; Michael S Hershfield; Donald B Kohn; Alan S Wayne; Fabio Candotti
Journal:  Blood       Date:  2011-07-01       Impact factor: 22.113

5.  Lactate dehydrogenase (LD), alkaline phosphatase (ALP) isoenzymatic patterns in Iraqi children with visceral leishmaniasis before and after treatment with stibogluconate.

Authors:  Jasim Hameed Taher; Yassir Mustafa Kamal Al-Mulla Hummadi; Nada Muhammed Taha Al-Bashir; Ali Shaalan Al-Araji
Journal:  J Parasit Dis       Date:  2014-06-22

6.  polyethylene glycol-conjugated adenosine deaminase (ADA) therapy provides temporary immune reconstitution to a child with delayed-onset ADA deficiency.

Authors:  Elke Lainka; Michael S Hershfield; Ines Santisteban; Pawan Bali; Annette Seibt; Jennifer Neubert; Wilhelm Friedrich; Tim Niehues
Journal:  Clin Diagn Lab Immunol       Date:  2005-07

7.  Immunologic reconstitution during PEG-ADA therapy in an unusual mosaic ADA deficient patient.

Authors:  Ping Liu; Ines Santisteban; Lauri M Burroughs; Hans D Ochs; Troy R Torgerson; Michael S Hershfield; David J Rawlings; Andrew M Scharenberg
Journal:  Clin Immunol       Date:  2008-10-25       Impact factor: 3.969

8.  Coronary artery disease: a study on the joint role of birth weight, adenosine deaminase, and gender.

Authors:  F Gloria-Bottini; M Banci; P Saccucci; N Lucarini; F Ianniello; G Paradisi; A Magrini; E Bottini
Journal:  Cardiol Res Pract       Date:  2010-04-13       Impact factor: 1.866

9.  Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans.

Authors:  Fabio Candotti; Kit L Shaw; Linda Muul; Denise Carbonaro; Robert Sokolic; Christopher Choi; Shepherd H Schurman; Elizabeth Garabedian; Chimene Kesserwan; G Jayashree Jagadeesh; Pei-Yu Fu; Eric Gschweng; Aaron Cooper; John F Tisdale; Kenneth I Weinberg; Gay M Crooks; Neena Kapoor; Ami Shah; Hisham Abdel-Azim; Xiao-Jin Yu; Monika Smogorzewska; Alan S Wayne; Howard M Rosenblatt; Carla M Davis; Celine Hanson; Radha G Rishi; Xiaoyan Wang; David Gjertson; Otto O Yang; Arumugam Balamurugan; Gerhard Bauer; Joanna A Ireland; Barbara C Engel; Gregory M Podsakoff; Michael S Hershfield; R Michael Blaese; Robertson Parkman; Donald B Kohn
Journal:  Blood       Date:  2012-09-11       Impact factor: 22.113

10.  Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID).

Authors:  Claire Booth; H Bobby Gaspar
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.